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Abstract: In this study, we investigated the role of IL-26 in allergic contact dermatitis (ACD), 
highlighting its contribute in the cytotoxic mechanism responsible of the tissue injury. IL-26 
is a signature Th17 cytokine, and immune cells are its predominant sources. Recently, it has 
shown that Th17 cell-derived-IL-26 functions like an antimicrobial peptide. Here, we 
hypothesized that IL-26 could be involved in cytotoxicity mechanism, that underlies ACD. 
Indeed, we have attributed a role to IL-26 in this context, through PBMC cytotoxicity assays 
versus Hacat. In order to demonstrate that IL-26 was effectively involved in this activity, we 
performed the assay using transfected ACD PBMCs by siRNA for IL-26. Indeed, we 
demonstrated that these cells were less able to kill keratinocytes compared to ACD PBMC 
(p<0.01). In conclusion, our findings support the idea that this emergent cytokine, IL-26, is 
implicated in the killing mechanisms of KC observed during ACD. 
 
Background  
Despite considerable progress in understanding the development of hapten-specific 
immunity, less is known about mechanisms responsible for tissue injury during allergic 
contact dermatitis (ACD) (1). Indeed, ultrastructural studies of ACD revealed damaged 
keratinocytes in close contact with mononuclear cells (1), suggesting a role for T cell-
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
mediated cytotoxicity (2). In particular, cytotoxic T cells activity becomes evident in the 
appearance of lesions, but subpopulations of T-helper (Th) cells also contribute to the release 
of specific cytokines (3). Today, there is experimental evidence to classify ACD amongst 
other inflammatory skin disorders as interleukin 17-producing T helper cells (Th17)-mediated 
disease (4). Indications for involvement of Th17, in particular the subpopulation cytotoxic T, 
in human skin allergy were reported for the first time in 2009 (5). The expression of 
interleukin-26 (IL-26) by Th17 was first described in 2007 (6). In humans, IL-26 is a 
signature Th17 cytokine, and its expression is regulated by IL-1β, IL-23 and RORγt. Immune 
cells, including Th1, Th17 and NK cells are predominant sources of IL-26. It induces the 
secretion of pro-inflammatory cytokines and chemokines by myeloid cells and favors the 
generation and local recruitment of Th17 cells (6). IL-26, emerging member of IL-10 family 
cytokines, stands distinct as it exerts antimicrobial response not only by priming various 
innate immune cells and modulating antiviral responses but also by eliciting direct 
microbicidal action through affecting the formation of membrane pores (7). Indeed, it has 
been shown that Th17 cell-derived-IL-26 functions like an antimicrobial peptide killing 
bacteria, through its ability to form multimers (8). Taken together all mentioned features 
confer a dual function to IL-26 both as potent natural antimicrobial and pro-inflammatory 
cytokine.  
Question addressed 
In this study, we investigated the role of IL-26 in ACD, highlighting its contribute in the 
cytotoxic mechanism responsible of tissue injury.  
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Experimental design  
The study population comprised 10 subjects affected by ACD, characteristics of these 
patients are listed in supplementary table-1 (ST-1), 10 by atopic dermatitis (AD), 10 by 
psoriasis and 15 age and sex matched healthy controls (HC). Skin biopsies as well as blood 
samples were taken from all patients. RNA and protein analysis was executed on skin 
biopsies and on peripheral blood mononuclear cells (PBMC). Moreover, circulating plasma 
levels of IL-26 were assessed. In vitro assays were performed with PBMC exposed to nickel 
sulphate (NiSO4) and toxic shock syndrome toxin 1 (TSST-1). In addition, PBMC 
cytotoxicity silenced or not for IL-26 was tested against HaCat cells by using the lactate 
dehydrogenase (LDH)-release assay.The sequences of the primers are listed in ST-2. Details 
in SM. 
 
Results 
IL-26 gene expression was significantly enhanced in ACD skin both non lesional (NLS) and 
lesional (LS) compared to healthy skin (HS) (p<0.01) (Fig.1a). A minor increase was 
observed in atopic dermatitis (AD) and PSO skin (p<0.05) (Fig.1a). Recently, it was reported 
that IL-19,  another member belonging to the same family of IL-26, was significantly 
enhanced in inducible eczema (ACD) respect to naturally occurring eczema (AD, nummular 
or dyshidrotic eczema) (9). Immunohistochemical analysis revealed a strong positivity for IL-
26 in infiltrating cells of ACD lesional skin (Fig.1b). Consistent with this observation, to 
better characterize this positive staining, we assessed IL-26 in PBMC from ACD subjects by 
immunofluorescence analysis (Fig.1c,d). A striking difference was observed in ACD vs 
healthy subjects. To confirm this finding, we determined IL-26 circulating plasma levels and 
they were significantly increased in ACD respect to HC subjects (p<0.05) (Fig.1e). 
Moreover, gene expression of granzyme B and granulysin, main cytotoxicity mediators, was 
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enhanced in all examined conditions respect to HS and in particular ACD showed the highest 
increase (Fig.2a,b). Data from literature show that the number of cytotoxic T cells was 
significantly increased in ACD and AD compared to PSO (10,11), suggesting that such cell-
mediated cytotoxic mechanisms may play an integral part in the eczematous disorders. 
Regarding AD results, we found increased gene expression of  the above mentioned 
cytotoxicity mediators, even though these were not higher than ones in PSO; we hypothesize 
that this difference is ascribable to chronic phase of our AD subjects. To date, the 
mechanisms leading to keratinocyte damage and spongiosis in ACD have so far remained 
unclear. Indeed, in order to deepen this point, we have analyzed IL-26 expression in PBMC, 
stimulating these cells in vitro with toxic shock syndrome toxin 1 (TSST-1) and nickel 
sulphate (NiSO4). IL-26 was highly expressed in PBMC from ACD patients and the 
stimulations were able to induce a further increase, even though not significant (Fig.2c). 
These findings showed that ACD PBMC have a considerable amount of IL-26 at basal 
conditions, fitting with the elevated levels already found in immunofluorescence. Thus, it 
would seem that IL-26 levels, unlike previously analyzed cytokines (12), are allergen 
independent in ACD PBMC. It is not surprising that in vitro models don’t always elicit 
adequate responses, indeed it has been demonstrated that although present in ACD, Th17 are 
not responsive to nickel treatment in vitro (5). Given that it has been demonstrated a 
cytotoxic role for IL-26 versus different bacteria, (8) we hypothesized that IL-26 could be 
involved in cytotoxicity mechanisms, that underlie ACD. Firstly, ACD PBMC were 
transfected with IL-26 siRNA and cytotoxicity mediators were assessed. Both granzyme B 
and granulysin gene expression were significantly decreased (p<0.05) in IL-26 siRNA ACD 
PBMC respect to ACD PBMC without silencing (Fig.2d), suggesting a role for IL-26 in 
cytotoxic mechanisms. Subsequently, we deeper investigated this point through PBMC 
cytotoxicity assays versus Hacat. We observed that the cytotoxicity activity of ACD PBMC 
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was significantly enhanced respect to HC PBMC (p<0.05) (Fig.2e). Next, we performed the 
assay using IL-26 siRNA ACD PBMC. Results derived from silenced ACD PBMC showed 
that these cells were less able to kill keratinocytes compared to ACD PBMC (p<0.01) without 
silencing (Fig.2f).  
 
Conclusions 
It is well established that CD4+ and CD8+ cytotoxic T lymphocytes (CTLs) in humans 
represent the key actors of cytotoxicity. It has been hypothesized that in ACD, activated 
keratinocytes present haptens to both CD8+ and CD4+ CTLs which subsequently elicit tissue 
damage through granzyme B exocytosis (10). Furthermore, given that Ag-specific T cells 
represent the minor fraction of skin-infiltrating T cells, nonspecific T cell killing represents 
an efficient amplification mechanism of the initially Ag-specific allergic reaction, rendering 
virtually all T lymphocytes recruited at the site of skin inflammation capable to directly 
contribute to tissue damage (5). Taken together our findings suggest that IL-26 could play a 
crucial role in this amplification mechanism being an allergen independent cytokine highly 
expressed in ACD patients and constitutively ready to act in complex killing system proper of 
this disease. 
 
Figure legends  
Figure 1. IL-26 is increased in ACD. (a) IL-26 gene expression in ACD, AD and PSO skin 
as well as healthy skin (HS). Fold expression was obtained from LS and NLS skin vs HS of 
controls and normalized to 18S. Data are displayed as mean ± standard deviation (SD). 
Statistical analysis was performed by Mann-Whitney test. *P<0.05; **P<0.01. (b) 
Immunohistochemistry analysis of IL-26 in ACD lesional skin. (c-d) Immunofluorescence 
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analysis of IL-26 (green) in ACD and HC PBMC. The nuclei were stained with DAPI (blue). 
Magnification 20x. (e) IL-26 circulating plasma levels in ACD and healthy control (HC) 
subjects. Data are displayed as mean ± standard deviation (SD). Statistical analysis was 
performed by Mann-Whitney test. *P<0.05. 
Figure 2. IL-26 involvement in cytotoxicity. (a,b) Granzime B (GZM-B) and granulysin 
(GNLY) gene expression in ACD, AD and PSO skin as well as HS. Statistical analysis was 
performed by Mann-Whitney test. (*) Comparison ACD, AD and PSO fold increase vs HS; 
(#) Comparison ACD fold increase vs AD and PSO fold increase. #/*p<0.05; **p <0.01; (c) 
IL-26 gene expression in PBMC of HC and nickel-ACD subjects stimulated with toxic shock 
syndrome toxin (TSST)-1 and nickel (NiSO4). Data are displayed as mean ± SD.**P<0.01 
(d) GZM-B and GNLY gene expression in ACD PBMC with or without siRNA for IL-26. 
Statistical analysis was performed by paired t-test. Data are displayed as mean ± SD *P<0.05. 
(e) LDH release to measure the percentage of cytotoxicity versus Hacat cells of ACD PBMC 
respect to HC PBMC. *P<0.05 (f) LDH release to measure the percentage of cytotoxicity 
versus Hacat cells of ACD PBMC with or without siRNA for IL-26. As negative control 
siRNA was used an oligonucleotide with scrambled sequence (Ctrl-siRNA IL-26). *P<0.05; 
**P<0.01. 
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